complex genetic changes
Products + Services
superior mutation detection
Cell Line Processing
Optimization
Quality Control
Examines edits one cell at a time
Tracks complex rearrangements with 2kb resolution
Detects structural variations in off-target effects of CRISPR/Cas9
Unidirectional dGH probes
Unbiased, whole-genome assessment of all structural rearrangements
10x resoltution over G-banding
synthetic oligonucleotide-based FISH assay
2-3k base pairs
3x Signal/Resolution 6x the signal-to-noise ratio 50% lower background
Traditional G-banding and karyotyping analysis
Gold standard structural rearrangement detection
Applications
cell and gene therapies, gene editing, cancer studies,
radiation biodosimetry
Cell and Gene Therapy
Monitoring Cellular Engineering Outcomes
On/Off Target Effects
Orthogonal Data for Sequencing
Variant Discovery
Genomic Stability Assessment
Radiation Biodosimetry
directional Genome Hybridization (dGH)
Structural Rearrangements
Inversions
Translocations
KromaTiD News
Company News + Press
- KromaTiD Announces Launch of Cell Culture Services
- KromaTiD Announces EARLY ACCESS Launch of TP53/CEP17 Kit for Synthetic Oligonucleotide-Based FISH Assay
- KromaTiD Announces Launch of dGH SCREEN™
- Applied Spectral Imaging and KromaTiD announce strategic commercial partnership
- KromaTiD and dGH in-Site featured in Genetic Engineering & Biotechnology News
Videos, Presentations & Webinars
- KromaTiD: Who We Are
- What is directional Genome Hybridization (dGH)?
- KromaTiD’s Cell Culture Services Protocol
- Dr. Chris Tompkins and Erin Cross present webinar for the launch of dGH SCREEN™ for unbiased whole genome analysis of chromosomal structural rearrangements
- Dr. Lauren Kinner-Bibeau presents webinar on single-cell measurements of genomic inserts and transgenes
- KromaTiD presents at the 2020 virtual NextGen Omics Series
- KromaTiD CTO Dr. Chris Tompkins presents at the 2020 Cell & Gene Therapy Virtual Congress
Market News
- With CRISPR Gene Editing, Unique Treatments begin to Take Off for Rare Diseases
- Crispr/CAS9 Gene Editing Can Produce Unexpected Heritable Changes
- Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next Gen Allogenic T-Cell Therapy for Auto-Immune Disease
- Locus Biosceinces – Triangle Gene Editing CEO revolution in Life Sciences happening in the Triangle
- Bluebird Bio hits FDA clinical trial HOLD for gene therapy in Sickle Cell disease
- Regulating Gene-Editing Technology
- Study encourages cautious approach using CRISPR therapeutics